全文获取类型
收费全文 | 5183篇 |
免费 | 481篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 134篇 |
儿科学 | 163篇 |
妇产科学 | 82篇 |
基础医学 | 693篇 |
口腔科学 | 180篇 |
临床医学 | 562篇 |
内科学 | 917篇 |
皮肤病学 | 99篇 |
神经病学 | 314篇 |
特种医学 | 288篇 |
外科学 | 648篇 |
综合类 | 162篇 |
一般理论 | 5篇 |
预防医学 | 582篇 |
眼科学 | 56篇 |
药学 | 379篇 |
1篇 | |
中国医学 | 6篇 |
肿瘤学 | 411篇 |
出版年
2021年 | 65篇 |
2020年 | 60篇 |
2019年 | 91篇 |
2018年 | 73篇 |
2017年 | 74篇 |
2016年 | 75篇 |
2015年 | 92篇 |
2014年 | 121篇 |
2013年 | 164篇 |
2012年 | 195篇 |
2011年 | 202篇 |
2010年 | 145篇 |
2009年 | 112篇 |
2008年 | 171篇 |
2007年 | 213篇 |
2006年 | 203篇 |
2005年 | 206篇 |
2004年 | 191篇 |
2003年 | 175篇 |
2002年 | 175篇 |
2001年 | 145篇 |
2000年 | 151篇 |
1999年 | 136篇 |
1998年 | 87篇 |
1997年 | 83篇 |
1996年 | 80篇 |
1995年 | 62篇 |
1994年 | 69篇 |
1993年 | 69篇 |
1992年 | 119篇 |
1991年 | 180篇 |
1990年 | 127篇 |
1989年 | 108篇 |
1988年 | 113篇 |
1987年 | 89篇 |
1986年 | 104篇 |
1985年 | 87篇 |
1984年 | 79篇 |
1983年 | 64篇 |
1982年 | 59篇 |
1981年 | 51篇 |
1979年 | 79篇 |
1978年 | 52篇 |
1977年 | 58篇 |
1975年 | 58篇 |
1974年 | 58篇 |
1973年 | 53篇 |
1972年 | 52篇 |
1971年 | 49篇 |
1970年 | 47篇 |
排序方式: 共有5682条查询结果,搜索用时 15 毫秒
131.
132.
PCR-SSCP快速检测耐多药结核分枝杆菌 总被引:1,自引:0,他引:1
目的:了解本地区结核病耐药基因突变情况,探讨PCR-SSCP作为新的分子药敏试验方法在临床的应用价值。方法:通过提取耐INH、RFP、SM的肺结核患者痰中结核分枝杆菌DNA,进行PCR-SSCP分析,检测结核分枝杆菌rpoB、katG、rpsL基因是否存在突变,并与传统L-J药敏实验对照。结果:30株耐多药株中,耐RPF、INH、SM基因突变阳性率为90%(27/30)、63%(19/30)、53%(16/30)。3个基因联合突变共8株(26.7%),2个基因联合突变共18株(60%),即26株(86.7%)。单基因突变共2株,2株无基因突变。结论:通过PCR-SSCP方法可检测出绝大部分耐多药结核病的耐药基因,rpoB、katG、rpsL基因突变与本地区结核杆菌对RFP、INH、SM耐药性有关。与传统L-J药敏实验对比,PCR-SSCP是一种敏感、快速的指导临床用药的先进检测方法。 相似文献
133.
M.F. MANJI I. AL BADAWI† A. EL ENBABY & N. AL BAREEDY† 《International journal of gynecological cancer》2006,16(2):675-680
Female circumcision is a traditional practice common in African countries. It involves partial or total removal of external female genitalia. It has led to many complications, in particular, the scarring of the external genitalia. The consequence is a very narrow introitus making the intracavitary brachytherapy treatment component difficult when these women develop cancer of cervix. We present two such cases from our institution. Our aim is to make the radiation and gynecological oncologists, both in developed and developing countries, aware of this practice and the problems they can encounter in the management of such cases. Intracavitary brachytherapy is an important component in the potentially curative role of radiation therapy for cervical cancer. Every effort should be made to ensure that the sequelae of genital mutilation does not deprive these women of the same standard of care as the general population. 相似文献
134.
Nicholas Thatcher Wendi Qian Peter I Clark Penelope Hopwood Robert J Sambrook Robert Owens Richard J Stephens David J Girling 《Journal of clinical oncology》2005,23(33):8371-8379
PURPOSE: Ifosfamide, carboplatin, etoposide, and vincristine, alone and in combination, are highly active against small-cell lung cancer (SCLC). This trial was designed to investigate whether survival could be improved by a regimen of all four drugs (ICE-V) compared with standard chemotherapy in patients with SCLC and good performance status, and to assess the patients' quality of life (QL). PATIENTS AND METHODS: Patients were randomly assigned to receive six cycles of either ICE-V at 4-week intervals without dose reduction or standard chemotherapy administered according to local practice. The recommended standard control regimens were cyclophosphamide, doxorubicin, and etoposide; and cisplatin and etoposide. RESULTS: A total of 402 patients were randomly assigned, and 350 (87%) patients have died. Overall survival was longer in the ICE-V group (hazard ratio, 0.74; 95% CI, 0.60 to 0.91; P = .0049), median survival was 15.6 months in the ICE-V group and 11.6 months in the control group, and 2-year survival rates were 20% and 11%, respectively. There was no evidence that the relative survival benefit for ICE-V was less in extensive-stage than in limited-stage patients. An increased rate of septicemia was reported in the ICE-V group (15% v 7% in the control group), but this did not result in an increase in reported treatment-related deaths (four patients [2%] in both groups). The findings on QL were broadly similar in both groups, with some benefit in favor of ICE-V. CONCLUSION: Compared with standard chemotherapy, the ICE-V regimen improves overall survival without QL penalties, despite an increased but manageable level of toxicity. 相似文献
135.
Adam J. Prus Scott D. Philibin Alan L. Pehrson Chad L. Stephens Rhiannon N. Cooper Laura E. Wise Joseph H. Porter 《Drug development research》2005,64(1):55-65
Clozapine (CLZ) drug discrimination is used as a preclinical model to evaluate compounds for putative atypical antipsychotic properties. In rats, a 1.25 mg/kg CLZ training dose appears to have greater pharmacological specificity for atypical antipsychotic drugs than the traditional 5.0 mg/kg CLZ training dose; however, methodological differences among studies have precluded a direct comparison between these training doses. In the present study, rats were trained to discriminate a 5.0 mg/kg CLZ dose from vehicle in a two‐choice drug discrimination task using methods similar to those in a previous study from our laboratory that used a 1.25 mg/kg CLZ training dose. Clozapine produced full substitution (≥80% CLZ‐lever responding) for itself at the training dose (5.0 mg/kg). The atypical antipsychotics olanzapine, quetiapine, and ziprasidone also produced full substitution for 5.0 mg/kg CLZ, whereas the atypical antipsychotics risperidone and sertindole produced partial substitution (≥60% CLZ‐lever responding). The typical antipsychotic, thioridazine, produced full substitution for the 5.0 mg/kg CLZ training dose, but the typical antipsychotics chlorpromazine, fluphenazine, and haloperidol failed to substitute for clozapine. In a subgroup of 1.25 mg/kg CLZ‐trained rats, ziprasidone produced strong partial substitution (73.0 % CLZ‐lever responding) for the 1.25 mg/kg CLZ training dose. Based on these findings, some atypical antipsychotic drugs (i.e., quetiapine and ziprasidone) produce full substitution only for the 5.0 mg/kg CLZ training dose, whereas other atypical antipsychotic drugs (i.e., sertindole and risperidone) produce full substitution only for the 1.25 mg/kg CLZ training dose. Thus, both of these training doses are important for the screening of putative atypical antipsychotic drugs with the clozapine drug discrimination assay. Drug Dev. Res. 64:55–65, 2005. © 2005 Wiley‐Liss, Inc. 相似文献
136.
Jennifer R. Brown John C. Byrd Paolo Ghia Jeff P. Sharman Peter Hillmen Deborah M. Stephens Clare Sun Wojciech Jurczak John M. Pagel Alessandra Ferrajoli Priti Patel Lin Tao Nataliya Kuptsova-Clarkson Javid Moslehi Richard R. Furman 《Haematologica》2022,107(6):1335
Cardiovascular (CV) toxicities of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib may limit use of this effective therapy in patients with chronic lymphocytic leukemia (CLL). Acalabrutinib is a second-generation BTK inhibitor with greater BTK selectivity. This analysis characterizes pooled CV adverse events (AE) data in patients with CLL who received acalabrutinib monotherapy in clinical trials (clinicaltrials gov. Identifier: , NCT02029443, NCT02475681 and NCT02970318). Acalabrutinib was given orally at total daily doses of 100–400 mg, later switched to 100 mg twice daily, and continued until disease progression or toxicity. Data from 762 patients (median age: 67 years [range, 32–89]; median follow-up: 25.9 months [range, 0–58.5]) were analyzed. Cardiac AE of any grade were reported in 129 patients (17%; grade ≥3, n=37 [5%]) and led to treatment discontinuation in seven patients (1%). The most common any-grade cardiac AE were atrial fibrillation/flutter (5%), palpitations (3%), and tachycardia (2%). Overall, 91% of patients with cardiac AE had CV risk factors before acalabrutinib treatment. Among 38 patients with atrial fibrillation/flutter events, seven (18%) had prior history of arrhythmia or atrial fibrillation/flutter. Hypertension AE were reported in 67 patients (9%), 43 (64%) of whom had a preexisting history of hypertension; no patients discontinued treatment due to hypertension. No sudden cardiac deaths were reported. Overall, these data demonstrate a low incidence of new-onset cardiac AE with acalabrutinib in patients with CLL. Findings from the head-to-head, randomized trial of ibrutinib and acalabrutinib in patients with high-risk CLL (clinicaltrials gov. Identifier: NCT02337829) prospectively assess differences in CV toxicity between the two agents. NCT02477696相似文献
137.
138.
C J Stephens 《Drug and alcohol dependence》1987,20(2):115-127
The data reported are from a 20% probability sample (n = 2516) of all adult patients seeking care in the emergency room at San Francisco General Hospital during a 60-day period. Thirty-five percent (35%) of the injured and 18% of the non-injured reported drinking prior to the event. This paper compares the following variables related to drinking-in-the-event for injured and non-injured: drinking places, drinking companions, amount consumed, time lapsed between drinking and the event, effects of drinking and causality attributed by the patient to drinking and the event. When these variables were entered into a logistic regression to evaluate their predictive value on injury status, only time lapsed since the last drink and drug use prior to the event were predictive of injury with both being negatively associated with admission to the emergency room for an injury. Injuries were more likely than non-injuries to occur in close proximity to drinking (44% of injuries occurred in less than 1 h of the last drink), and close to a third of the injured attributed a causal association of drinking with the event, with 60% of these feeling they were drunk at the time of injury. 相似文献
139.
Scott Saxman Patrick J. Loehrer Sr. Keith Logie Doyle Stephens Frank Workman Daniel Scullin Lawrence H. Einhorn Rafat Ansari 《Investigational new drugs》1991,9(3):253-256
Forty-six previously untreated patients with advanced non-small cell lung cancer (NSCLC) were entered into a Hoosier Oncology Group phase II trial of daily oral etoposide 50 mg/m2/d. The dose limiting toxicity was granulocytopenia. The non-hematologic toxicity was mild, with only 19% of patients developing Grade 3 or 4 leukopenia. Two partial responses of 10 and 16 weeks duration were seen in 43 evaluable patients, for an overall response rate of 4%. We conclude that daily oral etoposide has minimal activity in advanced NSCLC, and does not improve response rates over conventional 1–5 day intravenous etoposide administration.from the Hoosier Oncology Group, the Walther Cancer Institute, Indianapolis, IN; Department of Medicine, Indiana University, Indianapolis, IN, USADr. Einhorn is the Walther American Cancer Society Professor of Clinical Oncology. 相似文献
140.
Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration
下载免费PDF全文
![点击此处可从《The oncologist》网站下载免费的PDF全文](/ch/ext_images/free.gif)